Generic Name and Formulations:
Ambenonium chloride 10mg; tabs.
Indications for MYTELASE:
Individualize. Usual range: 5–25mg 3 or 4 times daily. Increase gradually at intervals of 1–2 days. Some patients may require 50–75mg per dose. Increasing dosage above 200mg daily requires supervision by clinician aware of signs and treatment of overdose.
Concomitant atropine, mecamylamine, or any other ganglionic blocking agents.
Monitor closely; narrow margin between first appearance of side effects and serious toxic effects. Asthma. Parkinson's disease. Mechanical intestinal or urinary obstruction. Bradycardia. Cardiac conduction disorders. Elderly. Pregnancy. Nursing mothers: not recommended.
Overdosage (eg, excessive salivation, abdominal cramps, diarrhea, miosis, urinary urgency, sweating, nausea, increase in bronchial and lacrymal secretions, vomiting, muscle cramps, fasciculation of voluntary muscles, generalized malaise, anxiety, vertigo).
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a